Stock-market investors who had been fretting about the breadth of the market can take heart.
The Russell 2000
RUT, +0.08%
and Dow Transports
DJT, +0.11%
, which have lagged behind the benchmark S&P 500 for most of the year, are finally catching up.
stock technical analysis: NGL ENERGY PARTNERS LP(NGL)
Advisors’ Opinion:
- [By Lisa Levin]
On Friday, the energy sector proved to be a source of strength for the market. Leading the sector was strength from NGL Energy Partners LP (NYSE: NGL) and Legacy Reserves LP (NASDAQ: LGCY).
- [By Lisa Levin]
In trading on Thursday, energy shares were relative laggards, down on the day by about 0.87 percent. Meanwhile, top losers in the sector included NGL Energy Partners LP (NYSE: NGL), down 17 percent, and Contango Oil & Gas Company (NYSE: MCF), down 12 percent.
- [By Lisa Levin]
Shares of NGL Energy Partners LP (NYSE: NGL) were down around 24 percent to $16.40. NGL Energy Partners declared a quarterly distribution of $0.39 per unit and revised its fiscal year 2017 and fiscal year 2018 outlook.
stock technical analysis: Omega Protein Corporation(OME)
Advisors’ Opinion:
- [By Lisa Levin]
Omega Protein Corporation (NASDAQ: OME) shares dropped 21 percent to $20.65 after the company posted weak Q4 earnings.
Shares of Endeavour Silver Corp (NYSE: EXK) were down around 22 percent to $3.41. Endeavour Silver reported a Q4 loss of $5.2 million.
- [By Lisa Levin]
Omega Protein Corporation (NYSE: OME) was down, falling around 20 percent to $17.47 after the company reported weaker-than-expected results for its fourth quarter.
stock technical analysis: EPR Properties(EPR)
Advisors’ Opinion:
- [By Laurie Kulikowski]
Net operating cash flow has increased to $64.42 million or 19.61% when compared to the same quarter last year. The firm also exceeded the industry average cash flow growth rate of 9.39%.
The gross profit margin for EPR PROPERTIES is currently very high, coming in at 73.12%. Regardless of EPR’s high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, EPR’s net profit margin of 46.18% significantly outperformed against the industry.
- [By Laurie Kulikowski]
We rate EPR PROPERTIES as a Buy with a ratings score of B. This is driven by a number of strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company’s strengths can be seen in multiple areas, such as its revenue growth, increase in net income, good cash flow from operations, expanding profit margins and growth in earnings per share. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.
- [By Laurie Kulikowski]
EPR’s investment pipeline should drive about 6-7% earnings growth in 2016, and historically the company’s dividend growth has roughly equated to earnings growth. Starting with an above-average 6.5% yield, we find this compelling for income-oriented investors.
- [By Laurie Kulikowski]
EPR’s revenue growth has slightly outpaced the industry average of 6.1%. Since the same quarter one year prior, revenues slightly increased by 9.7%. This growth in revenue appears to have trickled down to the company’s bottom line, improving the earnings per share.
- [By Laurie Kulikowski]
EPR PROPERTIES has improved earnings per share by 11.8% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, EPR PROPERTIES reported lower earnings of $2.78 versus $3.13 in the prior year. This year, the market expects an improvement in earnings ($2.91 versus $2.78).
- [By Laurie Kulikowski]
The company, on the basis of net income growth from the same quarter one year ago, has significantly outperformed against the S&P 500 and exceeded that of the Real Estate Investment Trusts (REITs) industry average. The net income increased by 17.5% when compared to the same quarter one year prior, going from $42.71 million to $50.20 million.
stock technical analysis: THERMOGENESIS Corp.(KOOL)
Advisors’ Opinion:
- [By Lee Jackson]
Cesca Therapeutics Inc. (NASDAQ: KOOL) had a 10% owner come in with a big-time purchase. Boyalfe bought a total of 6,102,942 shares of the stock a $2.52. The total for the purchase was posted at $6,838, 237.The company develops and manufactures automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. Its stock traded on Friday’s close at $3.45, so a well-timed buy.The 52-week range is $1.60 to $7.39. The consensus price targetis $2.
stock technical analysis: Sapiens International Corporation N.V.(SPNS)
Advisors’ Opinion:
- [By Lisa Levin] Gainers
Trevena Inc (NASDAQ: TRVN) rose 10.8 percent to $3.60 in pre-market trading after dropping 4.97 percent on Wednesday.
Yum China Holdings Inc (NYSE: YUMC) rose 10.2 percent to $31.05 in pre-market trading after the company reported upbeat earnings for its first quarter.
Seres Therapeutics Inc (NASDAQ: MCRB) rose 9.1 percent to $11.39 in pre-market trading after dropping 5.26 percent on Wednesday.
Plug Power Inc (NASDAQ: PLUG) rose 8.9 percent to $2.45 in pre-market trading after surging 73.08 percent on Wednesday.
Coach Inc (NYSE: COH) rose 6.7 percent to $41.98 in pre-market trading. Coach named Ian Bickley as President, Global Business Development and Strategic Alliances.
Sapiens International Corporation N.V. (NASDAQ: SPNS) shares rose 6.1 percent to $13.91 in pre-market trading after gaining 0.54 percent on Wednesday.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) rose 6.1 percent to $149.15 in pre-market trading. Jazz Pharma reached a settlement with Hikma Pharma related to Xyrem patent case. Mizuho downgraded Jazz from Buy to Neutral.
Interactive Brokers Group, Inc. (NASDAQ: IBKR) shares rose 6 percent to $36.72 in pre-market trading after declining 0.03 percent on Wednesday.
Rewalk Robotics Ltd (NASDAQ: RWLK) rose 5.3 percent to $2.00 in pre-market trading after the company disclosed that the U.S. Department of Veterans Affairs purchased 28 added Exoskeleton Systems.
Merrimack Pharmaceuticals Inc (NASDAQ: MACK) rose 5.1 percent to $3.29 in pre-market trading. Merrimack declared a $1.06 special dividend.
BioTime, Inc. (NYSE: BTX) shares rose 4.8 percent to $3.50 in pre-market trading. BioTime, reported the formation of new subsidiary AgeX Therapeutics, Inc.
Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) shares rose 4.8 percent to $12.26 in pre-market trading after gaining 0.69 percent on Wednesday.
Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 3.6 percent to $39.15 in pre-market trading after the company posted better-than
